High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma

In a previous study of gene array data, the authors identified survivin as a candidate marker of aggressiveness in clear cell renal cell carcinoma (ccRCC). What remained in question was whether survivin expression at the protein level is an independent predictor of disease progression and cancer‐specific survival.

[1]  J. Cheville,et al.  Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness , 2005, Cancer.

[2]  J. Cheville,et al.  Clear Cell Renal Cell Carcinoma: Gene Expression Analyses Identify a Potential Signature for Tumor Aggressiveness , 2005, Clinical Cancer Research.

[3]  J. Cheville,et al.  A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. , 2005, Clinics in laboratory medicine.

[4]  J. Lam,et al.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. , 2005, The Journal of urology.

[5]  T. Ratliff.  Innovations and Challenges in Renal Cancer: Consensus Statement From the First International Conference , 2005 .

[6]  M. P. Holloway,et al.  Survivin splice variants regulate the balance between proliferation and cell death , 2005, Oncogene.

[7]  F. Li,et al.  Role of survivin and its splice variants in tumorigenesis , 2004, British Journal of Cancer.

[8]  Tak W. Mak,et al.  Pathways of apoptotic and non-apoptotic death in tumour cells , 2004, Nature Reviews Cancer.

[9]  D. Altieri,et al.  Full-length dominant-negative survivin for cancer immunotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  John Calvin Reed,et al.  Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res., 9:6523-6533, 2003. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  D. Altieri.  Survivin, versatile modulation of cell division and apoptosis in cancer , 2003, Oncogene.

[12]  J. Cheville,et al.  Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma , 2003, Cancer.

[13]  J. Koziol,et al.  Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[15]  J. Cheville,et al.  Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. , 2002, American journal of clinical pathology.

[16]  C. Suschek,et al.  Differential subcellular localization of functionally divergent survivin splice variants , 2002, Cell Death and Differentiation.

[17]  N. Tanigawa,et al.  Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. , 2002, European journal of cancer.

[18]  C. Suschek,et al.  Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas , 2002, International journal of cancer.

[19]  M. Andersen,et al.  Survivin--a universal tumor antigen. , 2002, Histology and histopathology.

[20]  G. Krissansen,et al.  Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. , 2001, Journal of the National Cancer Institute.

[21]  D. Vaux,et al.  Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs , 2001, Genome Biology.

[22]  M. Kattan,et al.  A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.

[23]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Altieri,et al.  Inhibition of melanoma tumor growth in vivo by survivin targeting. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E Springer,et al.  Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. , 1999, Cancer research.

[27]  Alamdari,et al.  Follow‐up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy , 1999, BJU international.

[28]  C. Dinney,et al.  Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. , 1998, The Journal of urology.

[29]  B. Delahunt,et al.  Classification of renal cell carcinoma , 1997, Cancer.

[30]  R. Figlin,et al.  Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. , 1997, The Journal of urology.

[31]  K. Tohya,et al.  Sarcomatoid renal cell carcinoma , 2007, International Urology and Nephrology.

[32]  R. Flanigan.  Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness , 2006 .

[33]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[34]  A. Billis.  Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. , 2004, International braz j urol : official journal of the Brazilian Society of Urology.

[35]  R. Gaynor,et al.  Identification and Validation of Genes Involved in the Pathogenesis of Colorectal Cancer Using cDNA Microarrays and RNA Interference 1 , 2003 .

[36]  Roudebush Vamc,et al.  THE HEIDELBERG CLASSIFICATION OF RENAL CELL TUMOURS , 1997 .

[37]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[38]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.